We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Malfunctioning Transport Protein Causes Plaque Buildup in Alzheimer's Disease

By LabMedica International staff writers
Posted on 21 Jul 2009
A malfunction in the network of cells that forms the blood brain barrier allows the toxic buildup of amyloid plaque that characterizes Alzheimer's disease.

Investigators at the Saint Louis University School of Medicine (MO, USA) worked with a mouse model of human Alzheimer's disease to study the action of low-density lipoprotein receptor related protein-1 (LRP-1), the major brain-to-blood transporter of amyloid-beta proteins at the blood-brain barrier (BBB). More...
For this purpose, they developed specific antisense RNA to block the synthesis of LRP-1 and thereby deplete it from the cells of the BBB.

Results of this study, published in the July 2009 issue of the Journal of Alzheimer's Disease, revealed that these antisense RNAs in comparison to random antisense RNA selectively decreased LRP-1 expression, reduced BBB clearance of amyloid-beta protein, increased brain levels of amyloid-beta protein, and impaired learning ability and recognition memory in mice.

Having confirmed the importance of LRP-1 in transporting amyloid-beta protein out of the brain, the investigators looked at the factors that could affect LRP-1's ability to function. They reported in the May 2009 issue of the journal Brain Behavior and Immunity that inflammation was directly linked to the malfunction of LRP-1. They induced inflammation in the brains of mice with lipopolysaccharide (LPS) and found that inflammation increased brain levels of amyloid-beta protein by three mechanisms: increased influx, decreased efflux, and increased neuronal production.

Treatment of the mice with the anti-inflammatory drug indomethacin prevented inhibition of LRP-1 and tended to lower the concentration of amyloid-beta protein in the brains of the animals.

"We induced inflammation in mice and found that it turned off the LRP pump that lets amyloid-beta protein exit the brain into the bloodstream. It also revved up an entrance pump that transports amyloid-beta into the brain. Both of these actions would increase the amount of amyloid-beta protein in the brain," said senior author of both papers Dr. William A. Banks, professor of geriatrics and pharmacological and physiological science at the Saint Louis University School of Medicine. "Nonsteroidal anti-inflammatory drugs, especially indomethacin, have been associated with protection against Alzheimer's disease. Our work could influence that debate and thinking at the patient-care level."

Related Links:
Saint Louis University School of Medicine




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.